Novavax XBB Vaccine Update

Efficacy of the XBB vaccine is not available yet and will change by the time of release, if approved.

Novavax is preparing to have its XBB COVID vaccine ready by the end of September, calling it its “Priority #1” This will be the only non-MRNA, protein based vaccine available if approved.

Unfortunately we can't count on the efficacy being very strong or for it to last very long considering the earliest XBB variants are no longer circulating and the XBB.1.5 variant will likely be pushed out by more dominant variants by this Fall. The variants circulating are already much further evolved with many mutational changes that will undoubtedly impact efficacy.

We must slow down transmission to slow the pace of evolution which is currently much faster than influenza.

COVID weakens immune systems so a surge this summer sets up COVID, Flu, RSV and other respiratory spread viruses to rip through schools and homes this Fall and Winter putting more live's at risk and the long term health of tens of millions of people deteriorating.

We must upgrade the ventilation and filtration systems in schools. This is the most important step we can take to get control of respiratory spread pathogens.

"Novavax Reports Second Quarter 2023 Financial Results and Operational Highlights"

"Priority #1: Deliver an Updated COVID Vaccine for the Upcoming 2023 Fall Vaccination Season"

"During the second quarter, Novavax continued preparations to deliver our updated XBB COVID vaccine for the 2023 fall season. In most of our key target markets, including the U.S., the Novavax vaccine, if authorized, would be the only non-mRNA protein-based XBB COVID vaccine available."

"Continue to prepare to deliver our updated XBB COVID vaccine for the fall, consistent with recommendations from the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA) and World Health Organization.”

Initiated filing in the U.S., with submissions in the European Union (EU) and Canada to follow in the coming weeks."

"Manufacturing ongoing at commercial scale to supply global markets.”

“Fully deployed commercial teams across the U.S., EU and other select markets, with executed contracts to support market access"

"Received first Full Marketing Authorization in the EU for Nuvaxovid™ as a primary series in individuals aged 12 and older and as a booster in adults aged 18 and older"

Source: https://ir.novavax.com/press-releases/2023-08-08-Novavax-Reports-Second-Quarter-2023-Financial-Results-and-Operational-Highlights